Zenobia Therapeutics Announce A Partnership With The Alzheimer’s Drug Discovery Foundation
LA JOLLA, Calif., Aug. 14, 2012 /PRNewswire/ — Zenobia Therapeutics, the leader in fragment-based lead discovery for CNS disease announce today a strategic partnership to provide ADDF researchers access to Zenobia’s unique discovery platform.
The Zenobia team is composed of leaders in the fields of high-throughput structural biology and fragment-based lead discovery (FBLD). Their founders are pioneers of crystallographic and NMR fragment screening, and Zenobia’s FBLD approach is proven to identify specific and brain penetrable small molecules for central nervous system (CNS) indications. The Zenobia platform includes: a gene-to-structure platform with in-house cloning, expression and purification in E coli, insect and mammalian cells, a custom fragment library composed of diverse cores suitable for discovery of lead compounds that cross the blood-brain barrier, fragment screening by multiple validated methods and assay development (enzyme, cell and Drosophila). Zenobia will also provide access to their internal medicinal chemistry expertise to optimize the fragments to leads that are potent, selective and optimized for CNS ADME/PK properties.
For ADDF researchers, Zenobia will provide complementary consultation to establish joint research plans that utilize the Zenobia platform and assist in preparation of grant proposals. Once funded, Zenobia will continue to work closely with researchers to evolve the plans as the program progresses. In addition, Zenobia will offer their premier Fragment Library 1 at a reduced price to ADDF researchers.
Zenobia provides a commercial fragment library, and access to their structural biology, crystallography and fragment-based lead discovery expertise through partnerships, consulting and collaborations. Zenobia’s internal programs combine fragment-based lead discovery with the expertise of biologists and clinicians to find treatments for devastating neurodegenerative diseases which there is no disease altering treatment such as Alzheimer’s, Parkinson’s and Huntington’s disease. For additional information on Zenobia Therapeutics, Inc., contact Dr. Vicki Nienaber at email@example.com or visit www.zenobiatherapeutics.com. For additional information on Zenobia’s Fragment Library 1 or 2, contact Erika Zehm at firstname.lastname@example.org.
About the Alzheimer’s Drug Discovery Foundation
The mission of the Alzheimer’s Drug Discovery Foundation (ADDF) is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer’s disease, related dementias and cognitive aging. The ADDF has granted more than $51 million to fund over 370 Alzheimer’s drug discovery programs in academic centers and biotechnology companies in 18 countries. For more information about the ADDF, please visit www.alzdiscovery.org.
SOURCE Zenobia Therapeutics